Polymyxin B dosing in obese and underweight adults

Clinical Infectious Diseases

Volumn 57, Issue 12, 2013, Pages 1785-

  Pai, Manjunath P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; POLYMYXIN B;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DOSE REGIMEN; HUMAN; KIDNEY FUNCTION; LETTER; MINIMUM INHIBITORY CONCENTRATION; OBESITY; PRIORITY JOURNAL; UNDERWEIGHT;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; POLYMYXIN B;

EID: 84890072624     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit604     Document Type: Letter

References (5)

1. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin Infect Dis 2013; 57:524-31
2. Pai MP. Drug dosing based on weight and body surface area: Mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012; 32:856-68
3. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:3624-30
4. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/ pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65:1984-90
5. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on inhospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010; 65: 2231-7